pirfenidone has been researched along with Bright Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mitori, H; Mizukami, K; Noto, T; Takakura, K; Tomura, Y | 1 |
| Bao, L; Cho, IH; Hyun, BH; Kim, YJ; Lee, CH; Margolin, SB; Park, HS; Park, YH | 1 |
| Forslund, T; Iversen, BM; Leh, S; Margolin, SB; Vaagnes, Ø | 1 |
3 other study(ies) available for pirfenidone and Bright Disease
| Article | Year |
|---|---|
Antiproteinuric effect of pirfenidone in a rat model of anti-glomerular basement membrane glomerulonephritis.
Topics: Animals; Chemokine CCL2; Creatinine; Disease Models, Animal; Gene Expression Regulation; Glomerular Basement Membrane; Glomerulonephritis; Male; Proteinuria; Pyridones; Rats; RNA, Messenger | 2014 |
Pirfenidone suppressed the development of glomerulosclerosis in the FGS/Kist mouse.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Disease Models, Animal; Female; Fibrosis; Glomerular Filtration Rate; Glomerulonephritis; Kidney; Kidney Diseases; Male; Mice; Proteinuria; Pyridones; Sclerosis; Time Factors | 2003 |
Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats.
Topics: Analysis of Variance; Animals; Antibodies; Autoantibodies; Base Sequence; Benzimidazoles; Biopsy, Needle; Biphenyl Compounds; Blood Chemical Analysis; Blood Pressure Determination; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Glomerulonephritis; Immunohistochemistry; Kidney Function Tests; Male; Molecular Sequence Data; Probability; Pyridones; Random Allocation; Rats; Rats, Wistar; Reference Values; Renal Circulation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Statistics, Nonparametric; Tetrazoles | 2005 |